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Typhoid Immunization
Recommendations of the Advisory Committee on
Immunization Practices (ACIP)
Summary
These revised recommendations of the Advisory Committee on Immuniza-
tion Practices update previous recommendations (MMWR 1990;39[RR-10]:1–5).
They include information on the Vi capsular polysaccharide (ViCPS) vaccine,
which was not available when the previous recommendations were published.
INTRODUCTION
The incidence of typhoid fever declined steadily in the United States from 1900 to
1960 and has since remained low. From 1975 through 1984, the average number of
cases reported annually was 464. During that period, 57% of reported cases occurred
among persons ≥20 years of age; 62% of reported cases occurred among persons who
had traveled to other countries. From 1967 through 1976, only 33% of reported cases
occurred among travelers to other countries (1 ).
TYPHOID VACCINES
Three typhoid vaccines are currently available for use in the United States: a) an
oral live-attenuated vaccine (Vivotif Berna vaccine, manufactured from the Ty21a
strain of Salmonella typhi  (2 ) by the Swiss Serum and Vaccine Institute); b) a paren-
teral heat-phenol-inactivated vaccine that has been widely used for many years
(Typhoid Vaccine, manufactured by Wyeth-Ayerst); and c) a newly licensed capsular
polysaccharide vaccine for parenteral use (Typhim Vi, manufactured by Pasteur
Mérieux). A fourth vaccine, an acetone-inactivated parenteral vaccine, is currently
available only to the armed forces.
Although no prospective, randomized trials comparing any of the three U.S.-
licensed typhoid vaccines have been conducted, several field trials have demon-
strated the efficacy of each vaccine. In controlled field trials conducted among
schoolchildren in Chile, three doses of the Ty21a vaccine in enteric-coated capsules
administered on alternate days reduced laboratory-confirmed infection by 66% over a
period of 5 years (95% confidence interval [CI]=50%–77%) (3,4 ). In a subsequent trial
in Chile, efficacy appeared to be lower: three doses resulted in only 33% (95% CI=0%–
57%) fewer cases of laboratory-confirmed infection over a period of 3 years. When the
data were stratified by age in this trial, children ≥10 years of age had a 53% reduction
in incidence of culture-confirmed typhoid fever (95% CI=7%–77%), whereas children
5–9 years of age had only a 17% reduction (95% CI=0%–53%). This difference in age-
related efficacy, however, is not statistically significant (5 ). In another trial in Chile, a
significant decrease in the incidence of clinical typhoid fever occurred among persons
receiving four doses of vaccine compared with persons receiving two (p<0.001) or
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three (p=0.002) doses. Because no placebo group was included in this trial, absolute
vaccine efficacy could not be calculated (6 ).
Weekly and triweekly dosing regimens have been less effective than alternate-day
dosing (3 ). A liquid formulation of Ty21a is more effective than enteric-coated cap-
sules (5,7,8 ), but only enteric-coated capsules are available in the United States. The
efficacy of vaccination with Ty21a has not been studied among persons from areas
without endemic disease who travel to disease-endemic regions. The mechanism by
which Ty21a vaccine confers protection is unknown; however, the vaccine does elicit
both serum (2,9 ) and intestinal (10 ) antibodies and cell-mediated immune responses
(11 ). Vaccine organisms can be shed transiently in the stool of vaccine recipients (2,9 ).
However, secondary transmission of vaccine organisms has not been documented.
In field trials involving a primary series of two doses of heat-phenol-inactivated
typhoid vaccine (which is similar to the currently available parenteral inactivated vac-
cine), vaccine efficacy over the 21⁄2- to 3-year follow-up periods ranged from 51% to
77% (12–14 ). Efficacy for the acetone-inactivated parenteral vaccine, available only to
the armed forces, ranges from 75% to 94% (12,14,15 ).
The newly licensed parenteral vaccine (Vi capsular polysaccharide [ViCPS]) is com-
posed of purified Vi (“virulence”) antigen, the capsular polysaccharide elaborated by
S. typhi isolated from blood cultures (16 ). In recent studies, one 25-µg injection of
purified ViCPS produced seroconversion (i.e., at least a fourfold rise in antibody titers)
in 93% of healthy U.S. adults (17 ); similar results were observed in Europe (18 ). Two
field trials in disease-endemic areas have demonstrated the efficacy of ViCPS in pre-
venting typhoid fever. In a trial in Nepal, in which vaccine recipients were observed for
20 months, one dose of ViCPS among persons 5–44 years of age resulted in 74% (95%
CI=49%–87%) fewer cases of typhoid fever confirmed by blood culture than occurred
with controls (19 ). In a trial involving schoolchildren in South Africa who were 5–15
years of age, one dose of ViCPS resulted in 55% (95% CI=30%–71%) fewer cases of
blood-culture-confirmed typhoid fever over a period of 3 years than occurred with
controls. The reduction in the number of cases in years 1, 2, and 3, was 61%, 52%, and
50%, respectively (20,21 ). The efficacy of vaccination with ViCPS has not been studied
among persons from areas without endemic disease who travel to disease-endemic
regions or among children <5 years of age. ViCPS has not been tested among children
<1 year of age.
VACCINE USAGE
Routine typhoid vaccination is not recommended in the United States. However,
vaccination is indicated for the following groups:
• Travelers to areas in which there is a recognized risk of exposure to S. typhi. Risk is
greatest for travelers to developing countries (e.g., countries in Latin America, Asia,
and Africa) who have prolonged exposure to potentially contaminated food and
drink (22 ). Multidrug-resistant strains of S. typhi  have become common in some
areas of the world (e.g., the Indian subcontinent [23 ] and the Arabian peninsula
[24,25 ]), and cases of typhoid fever that are treated with ineffective drugs can be
fatal. Travelers should be cautioned that typhoid vaccination is not a substitute for
careful selection of food and drink. Typhoid vaccines are not 100% effective, and
the vaccine’s protection can be overwhelmed by large inocula of S. typhi. 
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• Persons with intimate exposure (e.g., household contact) to a documented S. typhi
carrier.
• Microbiology laboratorians who work frequently with S. typhi (26 ).
Routine vaccination of sewage sanitation workers is not warranted in the United
States and is indicated only for persons living in typhoid-endemic areas. Also, typhoid
vaccine is not indicated for persons attending rural summer camps or living in areas
in which natural disasters (e.g., floods) have occurred (27 ). No evidence has indicated
that typhoid vaccine is useful in controlling common-source outbreaks.
CHOICE OF VACCINE
The parenteral inactivated vaccine causes substantially more adverse reactions but
is no more effective than Ty21a or ViCPS. Thus, when not contraindicated, either oral
Ty21a or parenteral ViCPS is preferable.
Each of the three vaccines approved by the Food and Drug Administration has a
different lower age limit for use among children (Table 1). In addition, the time re-
quired for primary vaccination differs for each vaccine. Primary vaccination with
ViCPS can be accomplished with a single injection, whereas 1 week is required for
Ty21a, and 4 weeks are required to complete a primary series for parenteral inacti-
vated vaccine (Table 1). Finally, the live-attenuated Ty21a vaccine should not be used
for immunocompromised persons or persons taking antibiotics at the time of vaccina-
tion (see Precautions and Contraindications).














Primary series ≥6 yrs 1 capsule*  4 2 days —
Booster ≥6 yrs 1 capsule*  4 2 days every 5 yrs
Vi capsular poly-
saccharide vaccine
Primary series ≥2 yrs 0.50 mL†  1 — —





Primary series 6 mos–10 yrs  0.25 mL§  2 ≥4 wks —
≥10 yrs 0.50 mL§  2 ≥4 wks —
Booster 6 mos–10 yrs  0.25 mL§  1 — every 3 yrs
≥10 yrs 0.50 mL§  1 — every 3 yrs
≥6 mos 0.10 mL¶  1 — every 3 yrs
*Each orally administered capsule contains contains 2–6 x 109 viable S. typhi Ty21a and
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VACCINE ADMINISTRATION
Ty21a
Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-
coated capsule taken on alternate days for a total of four capsules. The capsules must
be kept refrigerated (not frozen), and all four doses must be taken to achieve maxi-
mum efficacy (6 ). Each capsule should be taken with cool liquid no warmer than 37 C
(98.6 F), approximately 1 hour before a meal. Although adverse reactions to Ty21a are
uncommon among children 1–5 years of age (28,29 ), data are unavailable regarding
efficacy for this age group. This vaccine has not been studied among children <1 year
of age. The vaccine manufacturer recommends that Ty21a not  be administered to
children <6 years of age.
ViCPS
Primary vaccination with ViCPS consists of one 0.5-mL (25-µg) dose administered
intramuscularly. This vaccine has not been studied among children <1 year of age. The
vaccine manufacturer does not recommend the vaccine for children <2 years of age.
Parenteral Inactivated Vaccine
Primary vaccination with parenteral inactivated vaccine consists of two 0.5-mL sub-
cutaneous injections, each containing approximately 5 x 10
8
 killed bacteria, separated
by ≥4 weeks. The vaccine manufacturer does not recommend the vaccine for use
among children <6 months of age. If the two doses of parenteral inactivated vaccine
cannot be separated by ≥4 weeks because of time constraints, common practice has
been to administer three doses of the vaccine at weekly intervals in the volumes listed
above. Vaccines administered according to this schedule may be less effective,
however.
Booster Doses
If continued or repeated exposure to S. typhi is expected, booster doses of vaccine
are required to maintain immunity after vaccination with parenteral typhoid vaccines
(Table 1). The ViCPS manufacturer recommends a booster dose every 2 years after the
primary dose if continued or renewed exposure is expected. In a study in which effi-
cacy was not examined, revaccination of U.S. adults at either 27 or 34 months after the
primary vaccination increased mean antibody titers to the approximate levels
achieved with the primary dose (17 ). The optimal booster schedule for persons ad-
ministered Ty21a for primary vaccination has not been determined; however, the
longest reported follow-up study of vaccine trial subjects indicated that efficacy con-
tinued for 5 years after vaccination (4 ). The manufacturer of Ty21a recommends
revaccination with the entire four-dose series every 5 years if continued or renewed
exposure to S. typhi  is expected. This recommendation may change as more data
become available about the period of protection produced by the Ty21a vaccine. If the
parenteral inactivated vaccine is used initially, booster doses should be administered
every 3 years if continued or renewed exposure is expected. A single booster dose of
parenteral inactivated vaccine is sufficient, even if >3 years have elapsed since the
prior vaccination. When the heat-phenol-inactivated vaccine is used for booster
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vaccination, the intradermal route causes less reaction than the subcutaneous route
(30 ). The acetone-inactivated vaccine should not be administered intradermally or by
jet- injector gun because of the potential for severe local reactions (31 ).
No information has been reported concerning the use of one vaccine as a booster
after primary vaccination with a different vaccine. However, using either the series of
four doses of Ty21a or one dose of ViCPS for persons previously vaccinated with
parenteral vaccine is a reasonable alternative to administration of a booster dose of
parenteral inactivated vaccine.
ADVERSE REACTIONS
Ty21a produces fewer adverse reactions than either ViCPS or the parenteral inacti-
vated vaccine. During volunteer studies and field trials with oral live-attenuated Ty21a
vaccine, side effects were rare and consisted of abdominal discomfort, nausea, vom-
iting, fever, headache, and rash or urticaria (2,7,32 ) (Table 2). In placebo-controlled
trials, monitored adverse reactions occurred with equal frequency among groups re-
ceiving vaccine and placebo.
In several trials, ViCPS produced fever (occurring in 0%–1% of vaccinees), head-
ache (1.5%–3% of vaccinees), and erythema or induration ≥1 cm (7% of vaccinees)
(17,20,33 ) (Table 2). In the study conducted in Nepal, the ViCPS vaccine produced
fewer local and systemic reactions than did the control (the 23-valent pneumococcal
vaccine) (19 ). Among schoolchildren in South Africa, ViCPS produced less erythema
and induration than did the control bivalent meningococcal vaccine (20 ). In a direct
comparison, ViCPS produced reactions less than half as frequently as parenteral inac-
tivated vaccine, probably because ViCPS contains negligible amounts of bacterial
lipopolysaccharide (33 ).
Parenteral inactivated vaccines produce several systemic and local adverse reac-
tions, including fever (occurring in 6.7%–24% of vaccinees), headache (9%–10% of
vaccinees), and severe local pain and/or swelling (3%–35% of vaccinees) (Table 2);
21%–23% of vaccinees missed work or school because of adverse reactions
(12,13,34 ). More severe reactions, including hypotension, chest pain, and shock, have
been reported sporadically.
TABLE 2. Common adverse reactions of typhoid fever vaccines
Vaccine
Reactions 
Fever Headache Local reactions    
Ty21a*   0%– 5%      0%– 5%   Not applicable
ViCPS   0%– 1%    1.5%– 3%   Erythema or
induration ≥1 cm: 7%
Parenteral inactivated 6.7%–24%      9%–10%   Severe local pain or
swelling: 3%–35%
*The side effects of Ty21a are rare and mainly consist of abdominal discomfort, nausea,
vomiting, and rash or urticaria.
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PRECAUTIONS AND CONTRAINDICATIONS
The theoretical possibility for decreased immunogenicity when Ty21a, a live bacte-
rial vaccine, is administered concurrently with immunoglobulin, antimalarials, or viral
vaccines has caused concern (35 ). However, because Ty21a is immunogenic even in
persons with preexisting antibody titers (29 ), its immunogenicity should not be af-
fected by simultaneous administration of immunoglobulin. Mefloquine can inhibit the
growth of the live Ty21a strain in vitro; if this antimalarial is administered, vaccination
with Ty21a should be delayed for 24 hours. The minimum inhibitory concentration of
chloroquine for Ty21a is >256 µg/mL; this antimalarial should not affect the immuno-
genicity of Ty21a (36,37 ). The vaccine manufacturer advises that Ty21a should not be
administered to persons receiving sulfonamides or other antimicrobial agents; Ty21a
should be administered ≥24 hours after an antimicrobial dose. No data exist on the
immunogenicity of Ty21a when administered concurrently or within 30 days of viral
vaccines (e.g., oral polio, measles/mumps/rubella, or yellow fever vaccines). In the
absence of such data, if typhoid vaccination is warranted, it should not be delayed
because of the administration of viral vaccines.
No data have been reported on the use of any of the three typhoid vaccines among
pregnant women. Live-attenuated Ty21a should not be used among immunocom-
promised persons, including those persons known to be infected with human
immunodeficiency virus. The two available parenteral vaccines present theoretically
safer alternatives for this group. The only contraindication to vaccination with either
ViCPS or with parenteral inactivated vaccine is a history of severe local or systemic
reactions following a previous dose.
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